About NIAID. (2012, February 29). Retrieved November 12, 2012, from National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/about/pages/default.aspx
Aldy, J. E., & Viscusi, W. K. (2008). Adjusting the Value of a Statistical Life for Age and Cohort Effects. The Review of Economics and Statistics, 90(3), 573–581.
American Academy of Pediatrics and American Academy of Family Physicians, Subcommittee on Management of Acute Otitis Media. (2004, May). Clinical Practice Guideline: Diagnosis and Management of Acute Otitis Media. Pediatrics, 1451-1465.
American Thoracic Society; Infectious Diseases Society of America. (2005). Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 171(4), 388–416.
Association of Medical Microbiology and Infectious Disease (AMMI) Canada Guidelines Committee. (2005). Complicated urinary tract infection in adults. Canadian Journal of Infectious Diseases & Medical Microbiology, 349-360.
Ball, C. G., Hansen, G., Harding, G. K., Kirkpatrick, A. W., Weiss, K., & Zhanel, G. G. (2010). Canadian practice guidelines for surgical intra-abdominal infections. Canadian Journal of Infectious Diseases & Medical Microbiology, 21(1), 11-37.
Barie, P. S., Rotstein, O. D., Dellinger, E. P., Grasela, T. H., & Walawander, C. A. (2004). The Cost-Effectiveness of Cefepime plus Metronidazole versus Imipenem/Cilastatin in the Treatment of Complicated Intra-Abdominal Infection. Surgical Interventions, 5(3), 269-280.
Barry, H. C., Ebell, M. H., & Hickner, J. (1997). Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. Journal of Family Practice, 49.
Ben-Haim, A. (2008). The POC Market for Diagnostics of Diabetes, Maternal and Child Health, Tuberculosis, Malaria and Diarrhoeal Diseases in India and the World. Chennai, India: IKP Centre for Technologies in Public Health (ICTPH).
Berndt, E. R., & Aitken, M. L. (2010). Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation. Cambridge, MA: National Bureau of Economic Research (NBER).
Berndt, E. R., Glennerster, R., Kremer, M. R., Lee, J., Levine, R., Weizsäcker, G., & Williams, H. (2005, January 5). Advanced Markets for a Malaria Vaccine: Estimating Costs and Effectiveness. MIT Sloan School of Management and NBER.
BIO Ventures for Global Health (BVGH). (2006). Tuberculosis Vaccines: The Case for Investment.
Blaue, G. E., Pekny, J. F., Varma, V. A., & Bunch, P. R. (2004). Managing a Portfolio of Interdependent New Product Candidates in the Pharmaceutical Industry. Journal of Product Innovation Management, 227-245.
Bryan, C. S., & Reynolds, K. L. (1984). Community-acquired bacteremic urinary tract infection: epidemiology and outcome. The Journal of Urology, 490-493.
Carson, C., & Naber, K. G. (2004). Role of Fluoroquinolones in the Treatment of Serious Bacterial Urinary Tract Infections. Drugs, 1359-1373.
Cattan, P., Yin, D. D., Sarfati, E., Lyu, R., de Zelicourt, M., & Fagnani, F. (2002). Cost of Care for Inpatients with Community-Acquired Intra-Abdominal Infections. European Journal of Clinical Microbiology & Infectious Diseases, 787–793.
Center for Drug Evaluation and Research (CDER). (2009, March). Guidance for Industry Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment. Retrieved November 8, 2011, from Food and Drug Administration: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati...
Center for Drug Evaluation and Research (CDER). (2010, August). Guidance for Industry: Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment (Draft Guidance). Retrieved June 27, 2012, from U.S. Food and Drug Administration: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati...
Center for Drug Evaluation and Research (CDER). (2010, November). Guidance for Industry: Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment (Draft Guidance). Retrieved November 9, 2011, from U.S. Food and Drug Administration: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati...
Center for Drug Evaluation and Research (CDER). (2012, February). Guidance for Industry Complicated Urinary Tract Infections: Developing Drugs for Treatment. Retrieved April 3, 2012, from U.S. Food and Drug Administration: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070981.pdf
Cepheid. (2008). Laboratory Instruments and Equipment FSC Group 66, Part III Cost-Per-Test FSC Class 6630. Department of Veterans Affairs Federal Supply Schedule Authorized Federal Supply Schedule Price List. Sunnyvale, CA: U.S. General Services Administration (GSA).
Cernuschi, T., Furrer, E., Schwalbe, N., Jones, A., Berndt, E. R., & McAdams, S. (2011). Advance Market Commitment for Pneumococcal Vaccines: Putting Theory into Practice. Bulletin of the World Health Organization, 89, 913-918.
Choe, J. (2012). Fewer Drugs, More Superbugs: Strategies to Reverse the Problem. Retrieved November 13, 2012, from Alliance for the Prudent Use of Antibiotics: http://www.tufts.edu/med/apua/news/news-newsletter-vol-30-no-1-5.shtml
Coco, A. S. (2007). Cost-Effectiveness Analysis of Treatment Options for Acute Otitis Media. Annals of Family Medicine, 5(1), 29-38.
Coco, A. S., Horst, M. A., & Gambler, A. S. (2009, June 24). Trends in broad-spectrum antibiotic prescribing for children with acute otitis media in the United States, 1998–2004. BMC Pediatrics, 9(41).
Coia, J., Duckworth, G., Edwards, D., Farrington, M., Fry, C., Humphreys, H., . . . Association, I. C. (2006). Guidelines for the Control and Prevention of Meticillin-resistant Staphylococcus Aureus (MRSA) in Healthcare Facilities. Journal of Hospital Infection, Vol 63 No. 1, S1-S44.
Collier, M. (2004, January). Recognition and Management of Wound Infections. Retrieved June 3, 2013, from World Wide Wounds: http://www.worldwidewounds.com/2004/january/Collier/Management-of-Wound-...
Congressional Budget Office (CBO). (1998). How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry. The Congress of the United States, Congressional Budget Office.
Cost-Effectiveness Analysis Registry. (n.d.). Retrieved June 19, 2012, from Tufts Medical Center: https://research.tufts-nemc.org/cear4/Home.aspx
Danzon, P. M., Pereira, N. S., & Tejwani, S. S. (2005). Vaccine Supply: A Cross-National Perspective. Health Affairs, 24(3), 706-717.
Datta, R., & Huang, S. S. (2008). Risk of Infection and Death due to Methicillin-Resistant Staphylococcus aureus in Long-Term Carriers. Clinical Infectitous Diseases, Vol. 47, 176-181.
DiMasi, J. A., & Grabowski, H. G. (2006). The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial And Decision Economics.
DiMasi, J. A., Grabowski, H. G., & Vernon, J. (2004). R&D Costs and Returns by Therapeutic Category. Drug Information Journal, 38, 211-223.
DiMasi, J., Hansen, R., & Grabowski, H. (2003). The price of innovation: new estimates of drug development costs. Journal of Health Economics, 22(2), 151-185.
Dong, J., Olano, J. P., McBride, J. W., & Walker, D. H. (2008). Emerging Pathogens: Challenges and Successes of Molecular Diagnostics. Journal of Molecular Diagnostics Vol. 10, No. 3, 185-197.
Drugs & Medications Search: Acute Otitis Media Infection. (2005-2012). Retrieved June 25, 2012, from WebMD: http://www.webmd.com/drugs/condition-1385-Acute+Otitis+Media+Infection.a...
Drummond, M. F., O'Brien, B., Stoddart, G. L., & Torrance, G. W. (1997). Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). Oxford University Press, GB.
Eastern Research Group, Inc. (2012). Economic Analysis of CDRH Submission Requirements. Lexington, MA: Eastern Research Group, Inc.
ECRI Institute. (2008). Rapid test to Screen for Methicillin-resistant Staphylococcus aureus (MRSA). Plymouth Meeting, PA: ECRI Institute.
Edelsberg, J., Taneja, C., Zervos, M., Haque, N., Moore, C., Reyes, K., . . . Oster, G. (2009, September). Trends in US Hospital Admissions for Skin and Soft Tissue Infections. Emerging Infectious Diseases, 15(9), 1516-1518.
EPA Office of Environmental Information. (2006). Data Quality Assessment: Statistical Methods for Practitioners, EPA QA/G-9S. Washington, DC: EPA Office of Environmental Information.
Eron, L. J., Lipsky, B. A., Low, D. E., Nathwani, D., Tice, A. D., & Volturo, G. A. (2003). Managing skin and soft tissue infections: expert panel recommendations on key decision points. Journal of Antimicrobial Chemotherapy, 52(Suppl. S1), i3–i17.
Evans, H., Lefrak, S., Lyman, J., Smith, R., Chong, T., McElearney, S., . . . Sawyer, R. (2007). Cost of Gram-negative resistance. Critical Care Medicine 35(1), 89-95.
Fast Track, Accelerated Approval and Priority Review. (2012, August 2). Retrieved November 7, 2012, from U.S. Food and Drug Administration: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedinga...
File, T., & Marrie, T. (2010). Burden of community-acquired pneumonia in North American adults. Postgraduate Medicine, 122(2), 130-41.
Fishbain, J. T., Lee, J. C., Nguyen, H. D., Mikita, J. A., Mikita, C. P., Uyehara, C. F., & Hospenthal, D. R. (2003). Nosocomial Transmission of Methicillin-resistant Staphlyococcus Aureus: A Blinded Study to Establish Baseline Acquisition Rates. Infection Control and Hospital Epidemiology, Vol. 24 No. 6, 415-421.
Flores-González, J. C., Hernández-González, A., Rodríguez-López, C., Roldán-Cano, V., Rubio-Quiñones, F., Quintero-Otero, S., . . . Pantoja-Rosso, S. (2011). Nosocomial urinary tract infection in critical pediatric patients. Medicina Intensiva, 344-348.
Foxman, B. (2002). Epidemiology of Urinary Tract Infections: Incidence, Morbidity, and Economic Costs. Excerpta Medica, 5S-13S.
Gold, M. R., Franks, P., McCoy, K. I., & Fryback, D. G. (1998). Toward Consistency in Cost-Utility Analyses: Using National Measures to Create Condition-Specific Values. Medical Care, 36(6), 778-792.
Gomez, P. L. (n.d.). Product Development: Moving from the Bench to the Clinic: Presentation at the Dale and Betty Bumpers Vaccine Research Center. Vaccine Research Center (NIH).
Grabowski, H. G., & Vernon, J. M. (2000). Effective Patent Life in Pharmaceuticals. International Journal of Technologfy Management, 19(1/2), 98-120.
Grabowski, H. G., Kyle, M., Mortimer, R., Long, G., & Kirson, N. (2011). Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act. Health Affairs Vol. 30 No. 11, 2157-2166.
Guleri, A., Kehoe, A., Hartley, J., Lunt, B., Harper, N., Palmer, R., . . . Jones, A. (2011). The Costs and Benefits of Hospital MRSA Screening. British Journal of Healthcare Management, Vol 17 No. 2, 64-71.
Hammitt, J. K., & Robinson, L. A. (2011). The Income Elasticity of the Value per Statistical Life: Transferring Estimates between High and Low Income Populations. Journal of Benefit-Cost Analysis, 2(1), 1-27.
Hay, M., Rosenthal, J., Thomas, D., & Craighead, J. (2011, February 15). Presentation: Clinical Trial Success Rates Study (BIO CEO & Investor Conference). Biotechnology Industry Organization (BIO) / BioMedTracker.
Hersh, A. L., Chambers, H. F., Maselli, J. H., & Gonzales, R. (2008, July 28). National Trends in Ambulatory Visits and Antibiotic Prescribing for Skin and Soft-Tissue Infections. Archives of Internal Medicine, 168(14), 1585-1591.
Honeycutt, A., Robinson, T., & Layton, C. (2005). Influenza Vaccine Economics (Issue Brief prepared by RTI International for the U.S. Department of Health and Human Services). Research Triangle Park, NC: RTI International.
Hooton, T. M., Bradley, S. F., Cardenas, D. D., Colgan, R., Geerlings, S. E., Rice, J. C., . . . Nicolle, L. E. (2010). Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clinical Infectious Diseases, 50, 625–663.
Huang, S. S., Johnson, K. M., Ray, G. T., Wroe, P., Lieu, T. A., Moore, M. R., . . . Finkelstein, J. A. (2011). Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine, 3398–3412.
IMS Health. (2010). Launch Evolution Across Pharmerging Markets: IMS Health LEAP Study 2010. Norwalk, CT: IMS Health.
IMS Health. (2012). National Sales Perspectives™, Year 2007-2011. Source File: 1205 antimicrobials sales 5-18-12.xls. Extracted May 2012.
Infectious Diseases Society of America . (2004). Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, A Public Health Crisis Brews. Alexandria, VA: Infectious Diseases Society of America.
Infectious Diseases Society of America (IDSA). (2012, April 12). Drug Companies, Health Groups Back IDSA Proposal. Retrieved November 13, 2012, from Infectious Diseases Society of America: http://www.idsociety.org/2012_LPAD_Proposal_Backing/#
Infectious Diseases Society of America (IDSA). (n.d.). Limited Population Antibacterial Drug (LPAD) Approval Mechanism: One-Page Summary. Retrieved November 13, 2012, from Infectious Diseases Society of America: http://www.idsociety.org/uploadedFiles/IDSA/News_and_Publications/IDSA_N...
Infectious Diseases Society of America. (2005, November 15). Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections. Clinical Infectious Diseases, 1373-1406.
Infectious Diseases Society of America. (2012). Limited Population Antibacterial Drug (LPAD) Approval Mechanism. Retrieved from http://www.idsociety.org/uploadedFiles/IDSA/News_and_Publications/IDSA_N...
Jernigan, J., & Kallen, A. (2010, March 24). Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: Activity C: ELC Prevention Collaboratives. Atlanta, GA: Centers for Disease Control and Prevention (CDC).
John K. Jenkins, M. (2011, December 8). CDER New Drug Review: 2011 Update - FDA/CMS Summit. Retrieved January 2, 2013, from http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProd...
Jones, R. N. (2010). Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. Clinical Infectious Diseases, 51(S1), S81–S87.
Kades, E. (2005). Preserving a Precious Resource: Rationalizing the Use of Antibiotics. Northwestern University Law Review, 611–674.
Kaper, J., Rappuoli, R., & Buckley, M. (2005). Vaccine Development: Current Status and Future Needs. Washington, D.C.: American Academy of Microbiology.
Kesselheim, A. S., & Outterson, K. (2010). Fighting Antibiotic Resistance: Marrying New Financial Incentives To Meeting Public Health Goals. Health Affairs, 29(9), 1689-1696.
Kesselheim, A. S., & Outterson, K. (2011). Improving Antibiotic Markets for Long Term Sustainability. Yale Journal of Health Policy, Law, and Ethics.
Kesselheim, A. S., & Outterson, K. (2011). Improving Antibiotic Markets for Long Term Sustainability. Yale Journal of Health Policy Law and Ethics, 101-167.
Klevens, R. M., Edwards, J. R., Richards, J. C., Horan, T. C., Gaynes, R. P., Pollock, D. A., & Cardo, D. M. (2007). Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002. Public Health Reports, 122(2), 160–166.
Kollef, M. H., Morrow, L. E., Niederman, M. S., Leeper, K. V., Anzueto, A., Benz-Scott, L., & Rodino, F. J. (2006). Clinical Characteristics and Treatment Patterns Among Patients With Ventilator-Associated Pneumonia. Chest, 1210-1218.
Lai, K. K., & Fontecchio, S. A. (2002, June). Use of silver-hydrogel urinary catheters on the incidence of catheter-associated urinary tract infections in hospitalized patients. American Journal of Infection Control, 221-225.
Lane, D. R., & Takhar, S. S. (2011). Diagnosis and Management of Urinary Tract Infection and Pyelonephritis. Emergency Medicine Clinics of North America, 539–552.
Laxminarayan, R., & Malani, A. (2007). Extending the Cure: Policy responses to the growing threat of antibiotic resistance. Washington, D.C.: Resources for the Future.
Layton, C., & Lenfestey, N. (2005). Influenza Vaccine Manufacturing (Issue Brief prepared by RTI International for the U.S. Department of Health and Human Services). Research Triangle Park, NC: RTI International.
Lee, B. Y., Bailey, R. R., Smith, K. J., Muder, R. R., Strotmeyer, E. S., Lewis, G. J., . . . Harrison, L. H. (2010, June). Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis. Infection Control and Hospital Epidemiology, 31(6), 598-606.
Levine, H. L. (2010, December). Vaccine Manufacturing Facilities of the Future (presentation by BioProcess Technology Consultants, BPTC).
Levy, S. B. (1992). The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle. New York: Plenum Press.
Lichtenberger, P., & Hooton, T. M. (2008). Complicated Urinary Tract Infections. Current Infectious Disease Reports, 10, 499–504.
Lipsky, M. S., & Sharp, L. K. (2001). From Idea to Market: The Drug Approval Process. The Journal of the American Board of Family Practice, 362-367.
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., . . . Chambers, H. F. (2011). Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children. Clinical Practice Guidelines, 1-38.
Lopez, N., Kobayashi, L., & Coimbra, R. (2011). A Comprehensive review of abdominal infections. World Journal of Emergency Surgery, 6.
Lutfiyya, M. N., Henley, E., Chang, L. F., & Reyburn, S. W. (2006). Diagnosis and Treatment of Community-Acquired Pneumonia. American Family Physician, 73(3), 442-450.
Marton, J. P., Jackel, J. L., Carson, R. T., Rothermel, C. D., Friedman, M., & Menzin, J. (2008). Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims. Current Medical Research and Opinion, 2821-2828.
Mayo Clinic. (2011, May 10). Pneumonia. Retrieved February 28, 2012, from Mayo Clinic: http://www.mayoclinic.com/health/pneumonia/DS00135/DSECTION=causes
Mazuski, J., & Solomkin, J. S. (2009). Intra-Abdominal Infections. Surgical Clinics of North America, 89, 421–437.
McEachern, R., & Campbell, J. G. (1998). Hospital-Acquired Pneumonia: Epidemiology, Etiology, and Treatment. Infectious Disease Clinics of North America, 12(3), 761-779.
Melekos, M. D., & Naber, K. G. (2000). Complicated urinary tract infections. International Journal of Antimicrobial Agents, 247–256.
Menzin, J., Marton, J. P., Meyers, J. L., Carson, R. T., Rothermel, C. D., & Friedman, M. (2010). Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. American Journal of Infection Control, 38(1), 44-49.
Merck. (2011). Community-Acquired Pneumonia. Retrieved February 28, 2012, from The Merck Manual Homehealth Handbook: http://www.merckmanuals.com/home/lung_and_airway_disorders/pneumonia/com...
Ming, D. Y., Chen, L. F., Miller, B. A., Sexton, D. J., & Anderson, D. J. (2012). The Impact of Depth of Infection and Postdischarge Surveillance on Rate of Surgical-Site Infections in a Network of Community Hospitals. Infection Control and Hospital Epidemiology, 276-282.
Mossialos, E., Morel, C. M., Edwards, S., Berenson, J., Gemmill-Toyama, M., & Brogan, D. (2010). Policies and incentives for promoting innovation in antibiotic research. European Observatory on Health Systems and Policies. Copenhagen, Denmark: World Health Organization.
Murphy, E. (2002). Weakened Defenses. Johns Hopkins Public Health: The Magazine of the Johns Hopkins Bloomberg School of Public Health.
National Center for Health Statistics. (1963, July). Length of Convalescence After Surgery. Series 10, Number 3.
National Hospital Discharge Survey. (2009). Table: Number and rate of discharges from short-stay hospitals and of days of care, with average length of stay, and standard error, by selected first-listed diagnostic categories: United States, 2009. Retrieved June 19, 2012, from Centers for Disease Control and Prevention: http://www.cdc.gov/nchs/data/nhds/2average/2009ave2_firstlist.pdf
National Hospital Discharge Survey. (2009). Table: Number, rate and average length of stay for discharges from short-stay hospitals by age, region, and sex: United States, 2009. Retrieved July 17, 2012, from Centers for Disease Control and Prevention: http://www.cdc.gov/nchs/data/nhds/1general/2009gen1_agesexalos.pdf
NIMH (National Institute of Mental Health). (2005). National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, FY 2005 Budget. Retrieved 2011, from http://www.nimh.nih.gov/about/budget/cj2005.pdf
Noskin, G. A., Rubin, R. J., Schentag, J. J., Kluytmans, J., Hedblom, E. C., Jacobson, C., . . . Bharmal, M. (2007, November 1). National Trends in Staphylococcus aureus Infection Rates: Impact on Economic Burden and Mortality over a 6-Year Period (1998–2003). Clinical Infectious Diseases, 45, 1132-1140.
Nugent, R., Back, E., & Beith, A. (2010). The Race Against Drug Resistance: A Report of the Center for Global Development’s Drug Resistance Working Group. Center for Global Development.
O'Brien, M. A., Prosser, L. A., Paradise, J. L., Ray, G. T., Kulldorff, M., Kurs-Lasky, M., . . . Lieu, T. A. (2009). New Vaccines Against Otitis Media: Projected Benefits and Cost-effectiveness. Pediatrics, 1452-1463.
Office of the Assistant Secretary for Preparedness and Response Organization Chart. (n.d.). Retrieved November 12, 2012, from U.S. Department of Health & Human Services: http://www.hhs.gov/about/orgchart/aspr.html
Okeke, I. N., Peeling, R. W., Goossens, H., Auckenthaler, R., Olmsted, S. S., de Lavison, J.-F., . . . Nordqvist, K. (2011). Diagnostics as Essential Tools for Containing Antibacterial Resistance. Drug Resistance Updates, 14(2), 95-106.
Outterson, K. (2006). The Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Intellectual Property Law. University of Pittsburgh Law Review, 67-123.
Outterson, K. (2010). The Legal Ecology of Resistance: The Role of Antibiotic Resistance in Pharmaceutical Innovation. Cardozo Law Review, 101-168.
Outterson, K., & Yevtukhova, O. (2011). Germ Shed Management in the United States. In I. M. Gould, & J. van der Meer (Eds.), Antibiotic Policies: Controlling Hospital-Associated Infection. Springer.
Outterson, K., Samora, J. B., & Keller-Cuda, K. (2007). Will Longer Antimicrobial Patents Improve Global Public Health? Lancet Infectious Disease, 559-566.
Paladino, J. A., Gilliland-Johnson, K. K., Adelman, M. H., & Cohn, S. M. (2008). Pharmacoeconomics of Ciprofloxicin plus Metronidazole vs. Piperacillin-Tazobactam for Complicated Intra-Abdominal Infections. Surgical Infections, 9(3), 325-333.
Parmet, S. (2003, September 24). JAMA Patient Page: Acute Otitis Media. The Journal of the American Medical Association, 290(12), 1666.
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010, March). How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery, 9, 203-214.
Peeling, R. W., Artsob, H., Pelegrino, J. L., Buchy, P., Cardosa, M. J., Devi, S., . . . Yoksan, S. (2010). Evaluation of diagnostic tests: Dengue. Nature Reviews Microbiology, s30-s37.
Pepper, P. V., & Owens, D. K. (2002, Sep-Oct). Cost-effectiveness of the pneumococcal vaccine in healthy younger adults. Medical Decision Making, 22(5 Suppl), S45-57.
Rajan, S. (2012, January). Skin and soft-tissue infections: Classifying and treating a spectrum. Cleveland Clinic Journal of Medicine, 79(1), 57-66.
Regan, T. L. (2008). Generic entry, price competition, and market segmentation in the prescription drug market. International Journal of Industrial Organization, 26, 930-948.
Rello, J., Ollendorf, D. A., Oster, G., Vera-Llonch, M., Bellm, L., Redman, R., & Kollef, M. H. (2002). Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database. Chest, 2115-2121.
Richards, R. J., & Hammitt, J. K. (2002). Timing of Prophylactic Surgery in Prevention of Diverticulitis Recurrence: A Cost-Effective Analysis. Digestive Diseases and Sciences, 47(9), 1903-1908.
Rickwood, S. (2010). Rising Payor Influence Means Successful Drug Launches are Rarer. IN VIVO, Vol 28 (4).
Ridley, D. B., Grabowski, H. G., & Moe, J. L. (2006). Developing Drugs For Developing Countries. Health Affairs, 25(2), 313-324.
Roberts, R. R., Douglas II, S. R., Hota, B., Kampe, L. M., Abbasi, F., Schabowski, S., . . . Weinstein, R. A. (2010). Costs Attributable to Healthcare-Acquired Infection in Hospitalized Adults and a Comparison of Economic Methods. Medical Care, 48(11), 1026-1035.
Roberts, R., Hota, B., Ahmad, I., Scott, R., Foster, S., Abbasi, F., . . . Weinstein, R. (2009). Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clinical Infectious Diseases 49(8), 1175-1184.
Rudholm, N. (2002). Economic Implications of Antibiotic Resistance in a Global Economy. Journal of Health Economics, 1071-1083.
Saint, S. (2000). Clinical and economic consequences of nosocomial catheter-related bacteriuria. American Journal of Infection Control, 68-75.
Sampathkumar, P. (2009). Nosocomial Pneumonia. In K. I. Bland, M. W. Büchler, A. Csendes, O. J. Garden, M. G. Sarr, & J. Wong (Eds.), General Surgery: Principles and International Practice (2nd Edition ed., pp. 287-295).
Sartelli, M. (2010). A focus on intra-abdominal infections. World Journal of Emergency Surgery, 5.
Sartelli, M., Catena, F., Coccolini, F., & Pinna, A. D. (2012). Antimicrobial management of intra-abdominal infections: Literature's guidelines. World Journal of Gastroenterology, 865-871.
Scherer, F. M. (2004). An Industrial Organization Perspective on the Influenza Vaccine Shortage (unpublished manuscript).
Schmitt, S. (2010, August 1). Community-Acquired Pneumonia. Retrieved November 8, 2011, from Cleveland Clinic Center for Continuing Education: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/infect...
Sharma, P., & Towse, A. (2011). New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options. London: Office of Health Economics Research.
Shorr, A. F., Susla, G. M., & Kollef, M. H. (2004). Linezolid for treatment of ventilator-associated penumonia: A cost-effective alternative to vancomycin. Critical Care Medicine, 32(1), 137-143.
Sloan, F. A., Berman, S., Rosenbaum, S., Chalk, R. A., & Griffin, R. B. (2004, December 2). The Fragility of the U.S. Vaccine Supply (presentation).
Smith, R., & Coast, J. (2013). The True Cost of Antimicrobial Resistance. BMJ Vol. 346, 1-5.
So, A. D., Gupta, N., Brahmachari, S. K., Chopra, I., Munos, B., Nathan, C., . . . Weigelt, J. (2011). Towards new business models for R&D for novel antibiotics. Drug Resistance Updates, 14, 88-94.
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J., Baron, E. J., . . . Bartlett, J. G. (2010). Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clinical Infectious Diseases, 50, 133–164.
Spirt, M. J. (2010). Complicated Intra-abdominal Infections: A Focus on Appendicitis and Diverticulitis. Postgraduate Medicine.
Stamm, W. E., & Hooten, T. M. (1993). Management of Urinary Tract Infections in Adults. The New England Journal of Medicine, 1328-1334.
Strongin, R. J. (2002). Hatch-Waxman, Generics, and Patents: Balancing Prescription Drug Innovation, Competition, and Affordability. Washingto DC: The George Washington University, National Health Policy Forum.
Struck, M. (1996). Vaccine R&D success rates and development times. Nature Biotechnology, 14, 591-593.
Sturkenboom, M. C., Goettsch, W. G., Picelli, G., Veld, B. i., Yin, D. D., de Jong, R. B., . . . Herings, R. M. (2005). Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. British Journal of Clinical Pharmacology, 438–443.
Tambyah, P. A., Knasinski, V., & Maki, D. G. (2002). The Direct Costs of Nosocomial Catheter-Associated Urinary Tract Infection in the Era of Managed Care. Infection Control and Hospital Epidemiology, 23(1), 27-31.
Tenover, F. C. (2011). Developing Molecular Amplification Methods for Rapid Diagnosis of Respiratory Tract Infections Caused by Bacterial Pathogens. Clinical Infectious Diseases Vol. 52, Supp 4, S338–S345.
U.S. Bureau of Economic Analysis. (2013). GDP & Personal Income. Retrieved June 2013, from U.S. Bureau of Economic Analysis: http://www.bea.gov/
U.S. Bureau of Labor Statistics. (1990-2011). Consumer Price Index - All Urban Consumers: Series IDs CUUR0000SAM,CUUS0000SAM (Medical Care). Retrieved July 3, 2012, from Bureau of Labor Statistics: http://data.bls.gov/pdq/querytool.jsp?survey=cu
U.S. Census Bureau. (2008, August 14). 2008 National Population Projections: Projected Population by Single Year of Age, Sex, Race, and Hispanic Origin for the United States: July 1, 2000 to July 1, 2050.
U.S. Centers for Disease Control and Prevention. (2013). Antibiotic Resistance Threats in the United States. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
U.S. Centers for Disease Control and Prevention. (2013, April 29). CDC Vaccine Price List. Retrieved June 2013, from U.S. Centers for Disease Control and Prevention: http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/pri...
U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. (2007). Urologic Diseases in America. Washington, D.C.: U.S. Government Printing Office.
U.S. Department of Labor. (2011). Establishment Data: Historical Hours and Earnings (Table B-2). Retrieved July 3, 2012, from U.S. Bureau of Labor Statistics: ftp://ftp.bls.gov/pub/suppl/empsit.ceseeb2.txt
U.S. Food and Drug Administration. (2007, April 17). System, Nucleic Acid Amplification Test, DNA, Methicillin Resistant Staphylococcus Aureus, Direct Specimen XPERT MRSA Test by Cepheid- 510(k) No. K070462. Retrieved from 510(k) Substantial Equivalence Determination Decision Summary: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K070462
U.S. Food and Drug Administration. (2012, March). Table of antibacterial drugs for Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
U.S. Food and Drug Administration. (2012, March). Table of antibacterial drugs for Community-Acquired Bacterial Pneumonia (CABP).
U.S. Food and Drug Administration. (2012, March). Table of antibacterial drugs for Complicated Intra-Abdominal Infections (CIAIs).
U.S. Food and Drug Administration. (2012, March). Table of antibacterial drugs for Complicated Urinary Tract Infections (CUTIs).
U.S. Food and Drug Administration. (2012, March). Table of antibacterial drugs for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia (HABP/VABP).
U.S. Food and Drug Administration. (2013, June 26). U.S. Food and Drug Administration. Retrieved from Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/SpeedingA...
U.S. National Center for Health Statistics. (2010, December 9). National Vital Statistics Report (NVSR): Deaths: Preliminary Data for 2008. Retrieved June 19, 2012, from http://www.census.gov/compendia/statab/cats/births_deaths_marriages_divo...
University of Michigan Health System. (2007, July). Guidelines for Clinical Care: Otitis media. 1-12. Ann Arbor, MI: University of Michigan Health System (UMHS).
Usdin, S. (2012, November 19). GAIN Act, FDA Stance Only First Steps to Refilling Antibiotic Pipeline in U.S. - Antibiotics Reset. Retrieved from BioCentury on BioBusiness: http://www.biocentury.com/biotech-pharma-news/coverstory/2012-11-19/gain...
Walters, D. J., Solomkin, J. S., & Paladino, J. A. (1999). Cost-Effectiveness of Ciprofloxacin plus Metronidazole versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections. Pharmacoeconomics, 16(5 Pt 2), 551-561.
Warren, D. K., Shukla, S. J., Olsen, M. A., Kollef, M. H., Hollenbeak, C. S., Cox, M. J., . . . Fraser, V. J. (2003). Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Critical Care Medicine, 31(5), 1312-1317.
Weigelt, J. A. (2007). Empiric treatment options in the management of complicated intra-abdominal infections. Cleveland Clinic Journal of Medicine, 74, S29-S37.